Company Overview and News
KUALA LUMPUR (Oct 1): The FBM KLCI notched up limited gains at the midday break today as decliners overtook advancers, against the backdrop of mixed regional markets.
APEXF 7084 7090 BATS 4162 0082 1163 5268 5256 6033 5199 0020 5843 0176 PNADF 1201 3301 7108 1899 2836 HIPEF PNAGF
KUALA LUMPUR (Aug 3): Kronologi Asia Bhd fell 2.86% in active trade this morning after the company said it plans to raise up to RM22.84 million via a placement of up to 10% of its shares to third-party investors to be identified later.
KUALA LUMPUR (Aug 3): The FBM KLCI is seen drifting lower Friday tracking the overnight losses at mot global markets on worries of an escalation in the trade dispute between the U.S. and China, with immediate support at 1,760.
0176 7173 AAPL 7158
KUALA LUMPUR (Aug 2): Based on corporate announcements and news flow today, companies in focus on Friday (Aug 3) may include: Fraser & Neave Holdings Bhd (F&N), Omesti Bhd, Toyo Ink Group Bhd, Kronologi Asia Bhd, Scomi Group Bhd and Unisem (M) Bhd.
0176 7173 7366 7158 7045
KUALA LUMPUR (Aug 2): AllianceDBS Research said Kronologi Asia Bhd (Krono) had on Aug 1 traded higher to 71.5 sen before settling near the day’s high at 70.5 sen (up 3 sen or 4.44%).
KUALA LUMPUR (July 19): AllianceDBS Research said Kronologi Asia Bhd (Krono) had on July 18 crossed over the 66 sen hurdle to reach a high of 67.5 sen before settling near the day’s high at 66.5 sen (up 3.5 sen or 5.55%).
KUALA LUMPUR (July 18): The FBM KLCI pared down its earlier losses substantially at mid-morning today, tracking the advance at key Asian markets.
7172 PBLOF 7053 8133 7087 1295 7153 7123 7079 0176 4588 3026 6645 5819
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...